Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma

Clear cell renal cell carcinoma (RCC) is characterized by inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene. VHL loss drives tumor angiogenesis and accounts for the clinical activity of VEGF receptor (VEGFR) tyrosine kinase inhibitors (TKIs), the first-line standard of care for advan...

Descripción completa

Detalles Bibliográficos
Autores principales: Tannir, Nizar M., Schwab, Gisela, Grünwald, Viktor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Evolving Therapies (R Bukowski, Section Editor)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5331092/
https://www.ncbi.nlm.nih.gov/pubmed/28247252
http://dx.doi.org/10.1007/s11912-017-0566-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5331092/
https://www.ncbi.nlm.nih.gov/pubmed/28247252
http://dx.doi.org/10.1007/s11912-017-0566-9

Ejemplares similares